Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

XNCR - Xencor, Inc. Последние новости | Finranks

Home

XNCR

(XNCR)

NGM – Цена в реальном времени. Валюта: USD

11.42

-0.89 (-7.23%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

11.20

-0.22 (-1.93%)

После закрытия: Mar 27, 2026, 4:47 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the “Licensee”) informed Xencor, Inc. (the “Company”) that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris® (ravulizumab-cwvz) in the United States and that the Licensee does not intend to make any.

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago.

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025. “Xencor's lead oncology drug candidate is XmAb819, a novel first-in-class T-cell engager that could offer a much-needed new therapeutic modality for patients with advanced clear cell renal cell carcinoma (ccRCC).

Xencor to Participate at Upcoming Investor Conferences

Xencor to Participate at Upcoming Investor Conferences

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen 46th Annual Health Care Conference Date: Monday, March 2, 2026 Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT Leerink Partners 2026 Global Healthcare Conference Date: Tuesday, March 10, 2026 Presen.

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline advancement milestones for its clinical-stage portfolio of novel XmAb® drug candidates. “Xencor designs proteins that enable potential first-in-class and best-in-class medicines for patients, and we are building on momentum from 2025, when we presented.

Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942

Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942

XNCR pairs a wholly owned antibody pipeline with XmAb platform partnerships. This way, they get milestones, licensing revenue, and royalties. This approach lets them partially fund their internal R&D. But on top of that, XNCR has ample liquid resources it can tap into as needed. XNCR's lead immunology asset XmAb942 is in Phase 2b for ulcerative colitis. And this candidate could help validate their ability to advance late-stage assets internally.

Видео

No Data

There is no data to display